Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED Corporation (CNMD) posted strong Q1 results, surpassing estimates and raising its 2025 outlook, driven by robust demand for BioBrace and AirSeal products and a high 86% recurring revenue base. The medical device manufacturer also achieved significant margin expansion, with adjusted gross margin improving to 56.4% and projected to reach 57% by Q4. Despite these operational strengths and projected 6% earnings growth for fiscal 2025, CNMD shares have significantly underperformed year-to-date, and the company faces notable headwinds including an estimated $5.5 million tariff impact in 2025, ongoing regulatory scrutiny, and persistent data security threats.

Analysis

CONMED Corporation (CNMD) demonstrates a significant disconnect between its robust operational performance and its recent stock valuation. The company delivered strong first-quarter results, beating both revenue and earnings estimates, and subsequently raised its 2025 outlook. Growth is being propelled by key products like BioBrace, which recently received FDA clearance for a new device, and the AirSeal platform, which is experiencing double-digit growth. Operationally, CNMD is strengthening its financial profile through margin expansion, with adjusted gross margin improving 80 basis points to 56.4% and projected to approach 57% by year-end, while operating margin grew 110 bps. This is supported by a highly stable business model, where 86% of revenue is recurring from single-use products. Despite these positive fundamentals and a projected 6% earnings growth for fiscal 2025, the stock has underperformed significantly, falling 22.7% year-to-date. This underperformance reflects persistent headwinds, including a quantifiable $5.5 million unfavorable tariff impact expected in 2025, potential compliance costs associated with its Class II medical device status, and significant cybersecurity risks.

Key Decisions for Investors

• Given the stark contrast between CNMD's strong operational metrics and its 22.7% year-to-date share price decline, investors should evaluate whether the current valuation adequately prices in the known risks or represents a potential dislocation.
• Closely monitor the identified headwinds, particularly any updates on the $5.5 million tariff impact, regulatory scrutiny from the FDA, and the company's management of cybersecurity threats, as these factors are key risks to the investment thesis.
• With supply chains improving and margins expanding, investors should watch for continued execution on growth drivers like BioBrace and AirSeal, as sustained fundamental performance could serve as a catalyst for a stock price recovery.